73 completed, 30 recruiting, 25 unknown, 17 terminated. 168 Phase 3, 13 Phase 2.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 3 | 168 | Completed 73, Recruiting 30, Unknown 25, Terminated 17, Active not recruiting 12, Not yet recruiting 6, Withdrawn 4, Suspended 1 |
| Phase 2 | 13 | Completed 3, Recruiting 3, Terminated 3, Unknown 3, Withdrawn 1 |
Follow Ovarian Cancer: new trials by email Literature Review of Ovarian Cancer trials Research Report on Ovarian Cancer
Trials (filtered) newest first · largest first
All 168 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1
INCB123667, Bevacizumab, Placebo - Ovarian Cancer | Phase 3 | Not yet recruiting | Incyte Corporation | 590 | 2026-12-01 | 2026-10-02 |
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer
Rina-S, Bevacizumab - Ovarian Cancer | Phase 3 | Not yet recruiting | Genmab | 602 | 2026-11-01 | 2026-10-05 |
A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer
Manganese Chloride, Nab-paclitaxel, Platinum chemotherapy - Ovarian Cancer | Phase 3 | Recruiting | Chinese PLA General Hospital | 120 | 2026-10-12 | 2026-09-16 |
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
R-DXd, Bevacizumab, Carboplatin - Ovarian Cancer, Peritoneal Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 646 | 2026-10-07 | 2026-10-16 |
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
R-DXd, Bevacizumab - Ovarian Cancer, Ovarian Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 802 | 2026-09-18 | 2026-10-21 |
Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer
trastuzumab, bevacizumab - Ovarian Cancer | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 420 | 2026-09-01 | 2026-08-21 |
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Rina-S, Bevacizumab, Carboplatin - Platinum-Sensitive Ovarian Cancer, Ovarian Cancer | Phase 3 | Recruiting | Genmab | 688 | 2026-08-28 | 2026-10-07 |
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Investigator's choice of Chemotherapy, Azenosertib - Ovarian Cancer | Phase 3 | Recruiting | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 420 | 2026-04-17 | 2026-08-12 |
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Rina-S, Bevacizumab - Ovarian Cancer, Platinum-sensitive Ovarian Cancer | Phase 3 | Recruiting | Genmab | 544 | 2026-04-03 | 2026-10-06 |
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Sacituzumab tirumotecan, Bevacizumab, Rescue Medications - Ovarian Neoplasms, Ovarian Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 900 | 2026-02-16 | 2026-10-13 |
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
INCB123667, Investigator's choice of chemotherapy - Ovarian Cancer | Phase 3 | Recruiting | Incyte Corporation | 466 | 2025-12-09 | 2026-10-15 |
A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancer
PIPAC - Ovarian Cancer | Phase 3 | Recruiting | tongweihua | 60 | 2025-11-10 | 2026-05-11 |
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin - Epithelial Ovarian Cancer, Ovarian Cancer | Phase 3 | Recruiting | Imunon | 500 | 2025-07-09 | 2026-10-05 |
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
PARP inhibitor + Bevacizumab, PARP inhibitor - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 / Phase 3 | Recruiting | N.N. Alexandrov National Cancer Centre | 120 | 2025-07-01 | 2026-03-16 |
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer
SHR-A1811, Chemotherapy - Ovarian Cancer | Phase 3 | Not yet recruiting | Tongji Hospital | 300 | 2025-06-01 | 2025-05-25 |
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Bevacizumab, Fluzoparib Monotherapy, Dietary Intervention - Ovarian Cancer | Phase 3 | Recruiting | Tongji Hospital | 424 | 2025-05-27 | 2025-06-24 |
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 770 | 2025-04-09 | 2026-10-13 |
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Trastuzumab Deruxtecan, Bevacizumab - Ovarian Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 582 | 2025-03-19 | 2026-07-02 |
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
HS-20089, Paclitaxel, Doxorubicin - Ovarian Cancer | Phase 3 | Recruiting | Hansoh BioMedical R&D Company | 468 | 2025-03-13 | 2025-12-17 |
A Study of SHR-A1811 in Subjects With Ovarian Cancer
SHR-A1811, Paclitaxel Injection, Doxorubicin Hydrochloride Liposome Injection - Ovarian Cancer | Phase 3 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 300 | 2025-03-13 | 2026-04-20 |
Showing 20 of 168. Sign in to see all of them.
Narrower conditions
Ovarian Neoplasms (168) · Fallopian Tube Neoplasms (54) · Carcinoma, Ovarian Epithelial (49) · Endometrial Neoplasms (10) · Breast Neoplasms (9) · Neoplasms (7) · Sarcoma (7) · Uterine Cervical Neoplasms (7) · Brenner Tumor (6) · Prostatic Neoplasms (6) · Recurrence (6) · Peritoneal Neoplasms (5) · Testicular Neoplasms (5) · Kidney Neoplasms (4) · Lung Neoplasms (4)
Broader conditions
Adnexal Diseases (168) · Endocrine Gland Neoplasms (168) · Endocrine System Diseases (168) · Female Urogenital Diseases (168) · Female Urogenital Diseases and Pregnancy Complications (168) · Genital Diseases (168) · Genital Diseases, Female (168) · Genital Neoplasms, Female (168) · Gonadal Disorders (168) · Neoplasms by Site (168) · Ovarian Diseases (168) · Urogenital Diseases (168) · Urogenital Neoplasms (168) · Neoplasms (161) · Neoplasms by Histologic Type (64)
Interventions
Paclitaxel (59) · Carboplatin (49) · Bevacizumab (26) · Topotecan (19) · Cisplatin (16) · liposomal doxorubicin (15) · Gemcitabine (14) · Doxorubicin (10) · Drug Therapy (10) · olaparib (8) · Cyclophosphamide (5) · Etoposide (5) · CP protocol (4) · Chemotherapy, Adjuvant (4) · Docetaxel (4)
Sponsors
Medical Research Council (7) · Merck Sharp & Dohme LLC (7) · AGO Study Group (6) · Gynecologic Oncology Group (6) · European Organisation for Research and Treatment of Cancer - EORTC (5) · Hoffmann-La Roche (5) · Jiangsu HengRui Medicine Co., Ltd. (4) · National Cancer Institute, Naples (4) · North Eastern German Society of Gynaecological Oncology (4) · Pfizer (4) · ARCAGY/ GINECO GROUP (3) · Amgen (3) · Genmab (3) · Nordic Society of Gynaecological Oncology - Clinical Trials Unit (3) · Novartis Pharmaceuticals (3)
Countries
United States (61) · Italy (50) · United Kingdom (44) · France (40) · Spain (40) · Belgium (39) · Germany (37) · China (36) · Canada (35) · Australia (28) · Poland (27) · South Korea (26) · Denmark (25) · Israel (24) · Netherlands (23)
Top investigators
Ignace B. Vergote, MD, PhD (3) · Jacobus Pfisterer, MD (3) · Jalid Sehouli (3) · Ciro Gallo, M.D., Ph.D. (2) · David S. Alberts, MD (2) · Francesco Perrone, M.D., Ph.D. (2) · Jonathan A. Ledermann, MD (2)
Results publications
PMID 37185961, PMID 37407274, PMID 16882940, PMID 16966687, PMID 21941283, PMID 30633128, PMID 10481771, PMID 12826431, PMID 12829663, PMID 14656276, PMID 15547181, PMID 15839957, PMID 16110020, PMID 16148284, PMID 16314640, PMID 16368440, PMID 16394300, PMID 16515585, PMID 17264340, PMID 17698804, PMID 17704410, PMID 17906207, PMID 17925548, PMID 17949799, PMID 18336399, PMID 18430468, PMID 18640939, PMID 18768432, PMID 19427025, PMID 19596139, PMID 20733132, PMID 20818904, PMID 20850296, PMID 20888993, PMID 21410972, PMID 21529904, PMID 21844495, PMID 22119995, PMID 22204725, PMID 22539562, PMID 22541893, PMID 22765965, PMID 22954508, PMID 22987083, PMID 23478059, PMID 23850170, PMID 24318743, PMID 24366937, PMID 24582486, PMID 24637997
NIH funding
2023 (5), 2025 (5), 2008 (4), 2009 (3), 2018 (3), 2015 (2), 2016 (2), 2019 (2), U10CA032102 (2), 2004 (1), 2005 (1), 2014 (1), 2017 (1), P30CA043703 (1), P30CA069533 (1)